By Devika Patel
Knoxville, Tenn., Sept. 30 - RegeneRx Biopharmaceuticals, Inc. said it will take in $3.7 million from a registered direct offering of shares.
The company will sell 4,512,195 common shares at $0.82 per share.
Investors also will receive warrants for 2,256,098 common shares. The warrants are exercisable at $1.12 for five years.
Roth Capital Partners and Boenning & Scattergood are the agents.
Settlement is expected Oct. 5.
Based in Bethesda, Md., RegeneRx is a biopharmaceutical company focused on the treatment of acute and chronic wounds.
| Issuer: | RegeneRx Biopharmaceuticals, Inc.
|
| Issue: | Common shares
|
| Amount: | $3.7 million
|
| Shares: | 4,512,195
|
| Price: | $0.82
|
| Warrants: | For 2,256,098 shares
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $1.12
|
| Agents: | Roth Capital Partners and Boenning & Scattergood
|
| Pricing date: | Sept. 30
|
| Settlement date: | Oct. 5
|
| Stock symbol: | Amex: RGN
|
| Stock price: | $1.12 at close Sept. 29
|
| Market capitalization: | $46.2 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
